Creo Medical’s H122 results highlighted its progress in developing and commercialising its minimally invasive electrosurgical devices. Creo’s core asset, Speedboat Inject, continued to gain traction in H122, supported by an initial licensing payment from Intuitive Surgical (signed in May 2022) and complemented by the mature European consumables business, which remains a stable revenue stream. We see upside potential from the multi-year collaboration with Intuitive Surgical but await further deta ....
14 Sep 2022
Creo Medical - Building momentum in 2022
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Creo Medical - Building momentum in 2022
Creo Medical Group Plc (CREO:LON) | 34.2 -0.2 (-1.4%) | Mkt Cap: 123.8m
- Published:
14 Sep 2022 -
Author:
Soo Romanoff -
Pages:
6
Creo Medical’s H122 results highlighted its progress in developing and commercialising its minimally invasive electrosurgical devices. Creo’s core asset, Speedboat Inject, continued to gain traction in H122, supported by an initial licensing payment from Intuitive Surgical (signed in May 2022) and complemented by the mature European consumables business, which remains a stable revenue stream. We see upside potential from the multi-year collaboration with Intuitive Surgical but await further deta ....